FDA CardioShield coverage for business development, investment, and market access teams
CardioShield has received FDA approval as the first treatment specifically designed for heart failure with preserved ejection fraction (HFpEF), offering new hope for patients.
We use cookies to enhance your experience, analyze traffic, and for marketing. By continuing to use our site, you consent to our use of cookies. Privacy Policy
